Zanubrutinib sold under the brand name 百悦泽 in china, is a BTK Inhibitor used to treat adults with: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).Waldenström’s macroglobulinemia (WM).Mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer.Marginal zone lymphoma (MZL) when the disease has come back or did not respond to treatment and who have received at least one certain type of treatment.
Chinese Version
Brand name：BRUKINSA (百悦泽)
INN name：Zanubrutinib (泽布替尼)
Manufacturer：BeiGene (百济神州)
Packaging：80mg*64c/Box
Inquire&E-mail: care@100pei.com
Zanubrutinib was approved by FDA for medical use in the United States in November 2019.
As of November 17, 2023, Zanubrutinib was approved for medical use in 44 countries around the world.
扫一扫 
